Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 5, 2019, Pages

  Poole, Phillippa ^a   Sathananthan, Kavin ^b   Fortescue, Rebecca ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; CARBOCISTEINE; CORTICOSTEROID; ERDOSTEINE; MUCOLYTIC AGENT; PLACEBO; EXPECTORANT AGENT;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MORTALITY RATE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BRONCHITIS, CHRONIC; DISEASE PROGRESSION; EXPECTORANTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85066826604     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001287.pub6     Document Type: Review

References (116)

1. Allegra L, Cordaro CI, Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: A multicenter, double-blind, placebo-controlled trial. Respiration 1996;63: 174-80.
2. Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. European Journal of Respiratory Disease 1980;61(111 Suppl): 93-108.
3. Bachh AA, Shah NN, Bhargava R, Ahmad Z, Pandey DK, Dar KA. Effect of oral N-acetylcysteine in COPD-a randomised controlled trial. JK-Practitioner 2007;14(1): 12-6.
4. Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis; report of a trial organized by the Swedish Society for Pulmonary Diseases. European Journal of Respiratory Disease 1983;64:405-15.
5. Bontognali E. Clinical effectiveness and tolerance of cithiolone in the prophylaxis of acute infective exacerbations in patients suffering from chronic bronchitis. Acta Therapeutica 1991;17:155-62.
6. Borgia M, Sepe N, Ori-Belometti M, Borgia R. Comparison between acetylcysteine and placebo in the long term treatment of chronic bronchitis [Confronto tra acetilcisteina e placebo nel trattamento a lungo termine della bronchite cronica]. Gazzetta Medica Italiana 1981;140:467-72.
7. Castiglioni CL, Gramolini C. Effect of long-term treatment with sobrerol on the exacerbations of chronic bronchitis. Respiration 1986;50:202-17.
8. Cegla UH. Long-term treatment of chronic bronchitis for two years with ambroxol (Mucosolvan) retard capsules. Results of a double blind trial including 180 patients [Langzeittherapie uber 2 Jahre mit Ambroxol (Mucosolvan) Retardkapseln bei Patienten mit chronischer Bronchitis. Ergebnisse einer Doppelblindstudie an 180 Patienten]. Praxis Klinik der Pneumologie 1988;42:715-21.
9. Cremonini C, Spada E, Cellini F, Cioni R, Giovannini M, Perri G, et al. I farmaci attivi sul muco nel trattamento di fondo della bronchite cronica [Pharmacotherapy which acts on mucus in long-term treatment of chronic bronchitis]. La Clinica Terapeutica 1986;116:121-9.
10. Calverley PMA, Page C, Dal Negro RW, Fontana G, Iversen M, Cicero AF, et al. Effect of erdosteine in moderately severe COPD patients. European Respiratory Journal. 2018; Vol. 52:PA776.
11. Calverley PMA, Page C, Dal Negro RW, Fontana G, Iversen M, Cicero AF, et al. Effect of erdosteine on the rate of COPD exacerbations in spirometrically defined Gold II patients. Respirology. 2017; Vol. 2:49.
12. Dal Negro RW, Iversen M, Calverly PM. Efficacy and safety of erdostein in COPD: Results of a 12-month prospective, multinational study. European Respiratory Journal 2015;46: PA1495.
13. Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: The RESTORE study. European Respiratory Journal 2017;50(4):1700711. DOI: 10.1183/13993003.00711-2017
14. Dal Negro RW, Wedzicha JA, Iversen MI, Fontana G, Page C, Cicero AF, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: The RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine). European Respiratory Journal. 2017; Vol. 50:PA675.
15. De Backer J, Vos W, Van Holsbeke C, Vinchurkar S, Claes R, Parizel P, et al. Double blind, randomized, twoway crossover, pilot study to assess the effect of high dose N-acetylcysteine on airway geometry, inflammation and oxidative stress in COPD patients using functional respiratory imaging. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187, issue A2447.
16. De Backer J, Vos W, Van Holsbeke C, Vinchurkar S, Claes R, Parizel PM, et al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 2013;8:569-79.
17. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebocontrolled trial. Lancet 2005;365(9470):1552-60.
18. Ekberg-Jansson A, Larson M, MacNee W, Tunek A, Wahlgren L, Wouters EFM, et al. N isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. European Respiratory Journal 1999;13(4):829-34.
19. Fukuchi Y, Tatsumi K, Inoue H, Sakata Y, Shibata K, Miyagishi H, et al. Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study. International Journal of Chronic Obstructive Pulmonary Disease 2016;11:831-8.
20. Ichinose M, Fukuchi Y, Tatsumi K, Inoue H, Arai T, Shibata K, et al. Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study. European Respiratory Journal 2015;46:PA4359.
21. Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. European Journal of Clinical Pharmacology 1976; 9:393-6.
22. Grassi C, Casali L, Ciaccia A, et al. [Terapia intervallare con l’associazione carbocisteina-sobrerolo nella profilassi delle riacutizzazioni della bronchite cronica]. Italian Journal of Chest Disease 1994;48:17-26.
23. Grillage M, Barnard-Jones K. Long-term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. British Journal of Clinical Practice 1985;39(10):395-8.
24. Hansen NC, Skriver A, Brorsen-Riis L, Balsløv S, Evald T, Maltbaek N, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respiratory Medicine 1994;88:531-5.
25. Jackson IM, Barnes J, Cooksey P. Efficacy and tolerability of oral acetylcysteine (fabrol) in chronic bronchitis: A doubleblind placebo controlled trial. Journal of International Medical Research 1984;12:198-206.
26. Johnson K, McEvoy CE, Naqvi S, Wendt C, Reilkoff RA, Kunisaki KM, et al. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: A randomized, placebo-controlled trial. International Journal of Chronic Obstructive Pulmonary Disease 2016;11:799-807.
27. Malerba M, Ponticello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Doubleblind, randomized, multi-center, placebo-controlled study (the AMETHIST trial). Pulmonary Pharmacology and Therapeutics 2004;17(1):27-34.
28. British Thoracic Society Research Committee. Oral Nacetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985;40(11):832-5.
29. Meister R. Long-term therapy with acetylcysteine retard tablets in patients with chronic bronchitis: A double-blind, placebo controlled study. Unpublished source 1986.
30. Beeh K-M, Beier J, Candler H, Wittig T. Effect of ELOM- 080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype-a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Chronic Obstructive Pulmonary Disease 2016;11(1):2877-84.
31. Meister R, Wittig T, Beuscher N, de Mey C. Efficacy and tolerability of myrtol standardized in long-term treatment of chronic bronchitis. A double-blind, placebo-controlled study. Study Group Investigators. Arzneimittelforschung 1999;49(4):351-8.
32. Moretti M, Bottrighi P, Dallari R, Da Porto R, Dolcetti A, Grandi P, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: The EQUALIFE study. Drugs Under Experimental and Clinical Research 2004;30(4):143-52.
33. Nowak D, Carati L, Pirozynski M. Long-term administration of N-acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study. European Respiratory Journal 1999;14 Suppl: 381S-2S.
34. Olivieri D, Zavattini G, Tomasini G, Daniotti S, Bonsignore G, Ferrara G, et al. Ambroxol for the prevention of chronic bronchitis exacerbations: Long-term multicenter trial. Respiration 1987;51 Suppl 1:42-51.
35. Parr GD, Huitson A. Oral fabrol (oral n-acetyl-cysteine) in chronic bronchitis. British Journal of Diseases of the Chest 1987;81(4):341-8.
36. Pela R, Calcagni AM, Subiaco S, Isidori P, Tubaldi A, Sanguinetti CM. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 1999;66(6):495-500.
37. Morgan EJ, Petty TL. Summary of the national mucolytic study. Chest 1990;97(Suppl):24S-7S.
38. Petty TL. The national mucolytic study: Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990;97(1):75-83.
39. Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlledrelease tablets in patients with chronic bronchitis. European Respiratory Journal 1988;1:351-5.
40. Roy P, Haran A, Srinivas BN. Role of n-acetylcysteine as an adjuvant to mainstay bronchodilator therapy in chronic obstructive pulmonary disease. Indian Journal of Pharmacology Conference Publication 2013;45:S107.
41. Roy P, Haran A, Srinivas BN, Mjumdar P. Evaluation of effect of N-acetylcysteine as an adjuvant to mainstay bronchodilator therapy in mild to moderate cases of chronic obstructive pulmonary disease. International Journal of Medical and Applied Sciences 2014;3(1):95-105.
42. Chavannes N, Schermer T, Wouters EFM, Folgering H. Demographic and clinical determinants of response to Nacetylcysteine versus fluticasone in mild to moderate COPD in primary care: The COOPT study. European Respiratory Journal 2005;26 (S49):1356.
43. Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, et al. Fluticasone and Nacetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine 2009;103:542-51.
44. Tse HN, Raiteri L, Wong KY, Ng LY, Yee KS, Tseng CZS. Benefits of high-dose N-acetylcysteine to exacerbationprone patients with COPD. Chest 2014;146(3):611-23.
45. Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, et al. High-dose N-acetylcysteine in stable COPD: The 1- year, double-blind, randomized, placebo-controlled HIACE study. Chest 2013;144:106-18.
46. Tse HN, Wong KY, Yee KS, Ng LY. The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients: A double blinded randomized placebo controlled trial. European Respiratory Journal 2012;40 Suppl 56:P2105.
47. Tse HN, Wong KY, Yee KS, Ng LY, Wai KY, Loo CK, et al. The effect of high dose N-acetylcysteine (600 mg twice daily) in patients with stable chronic obstructive pulmonary disease-a one-year, double blind, randomized, placebocontrolled trial. American Journal of Respiratory and Critical Care Medicine 2013;187:A2448.
48. Worth H, Schacher C, Dethlefsen U. Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial. Respiratory Research 2009;10(1):69.
49. Worth H, Schacher C, Dethlefsen U. Effects of concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial. European Respiratory Society 20th Annual Congress; 2010 Sep 18- 22; Barcelona. 2010; Vol. P538.
50. Xu X-G, Jiang Z-Y, Du M-J, Yang Y-Q, Jiang Y-C. Evaluation on effectiveness of salmeterol/fluticasone propionate combined with N-acetylcysteine in treatment of chronic obstructive pulmonary disease. [Chinese]. Journal of Jilin University Medicine Edition 2014;40(40):870-4.
51. Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): A randomised placebo-controlled trial. Lancet 2008;371 (9629):2013-8.
52. Papi A, Brusselle G, Sergio F, Pannacci M, Zheng J, Criner G. Blood eosinophils and smoking history affect outcome with high dose N-acetylcysteine treatment in COPD. European Respiratory Journal. 2017; Vol. 50:PA1066.
53. Papi A, Zheng J, Criner GJ, Fabbri LM, Calverley PMA. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study. Respiratory Medicine 2019;147:37-43.
54. Sergio F, Papi A, Criner G, Brusselle G, Calverley P, Fabbri L, et al. Long term treatment with n-acetylcysteine reduces moderate-severe exacerbations of chronic obstructive pulmonary disease. Respirology 2016;21:186.
55. Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, et al. High-dose N-acetylcysteine in the prevention of COPD exacerbations: Rationale and design of the PANTHEON study. COPD: Journal of Chronic Obstructive Pulmonary Disease 2013;10:164-71.
56. Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, et al. High-dose N-acetylcysteine in the prevention of COPD exacerbations: Results of the PANTHEON study. European Respiratory Society 23rd Annual Congress; 2013 Sep 7-11; Barcelona. 2013.
57. Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): A randomised, double-blind placebo-controlled trial. Lancet Respiratory Medicine 2014;2:187-94.
58. Baglioni S, Tazza R, Rossi S, Eslami A, Ferranti P, Dottorini M. Effects of N-acetylcysteine treatment during long term oxygen therapy (LTOT) in COPD patients. An open parallel-group study. European Respiratory Journal 2001;18(33 Suppl):58S.
59. Cattaneo C. Neltenexine tablets in smoking and nonsmoking patients with COPD. A double-blind, randomised, controlled study versus placebo. Minerva Medica 2001;92(4):277-84.
60. Andreasen T. Mucolytic treatment of chronic bronchitis during two winter periods. Scandinavian Journal of Respiratory Disease 1974;90:69-70.
61. Christensen SB, Kjer J, Ryskjaer S, Arseth-Hansen P, Christensen F. Mucolytic treatment of chronic bronchitis during two winter periods. Scandinavian Journal of Respiratory Disease 1971;52(1):48-57.
62. Edwards GF, Steel AE, Scott JK, Jordan JW. Scarboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction. Chest 1976;70(4): 506-13.
63. Habich G, Repges R. Chronic obstructive lung diseases: The efficacy of cineole [Cineol als medikation sinnvoll und bewart]. Therapiewoche 1994;44(6):356-65.
64. Kasielski M, Nowak D. Long-term administration of Nacetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respiratory Medicine 2001;95(6):448-56.
65. Lukas R, Scharling B, Schultze-Werninghaus G, Gillisen A. Administration of N-acetylcysteine and vitamin C to augment antioxidant properties in patients with chronic bronchitis. Deutsche Medizinishe Wochenscrift 2005;130: 563-7.
66. Maesen FP, Brombacher PJ. Treatment of chronic bronchitis with oral acetylcysteine, a double-blind study. European Journal of Respiratory Disease 1980;61:110.
67. Michnar M, Milanowski J. Assessment of efficacy and tolerability of the oral treatment of ambrosol in patients with chronic bronchitis [Ocena kliniczna skutecznosci i tolerancji doustnego leczenia ambrosolem u chorych na przewlekle zapalenie oskrzeli]. Pneumonologia i Alergologia Polska 1996;64(Suppl 1):90-6.
68. Moretti M, Ballabio M. Effect of erdosteine on airflow obstruction and symptom recovery in severe COPD exacerbations [Abstract]. European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. 2011; Vol. 38 (55):76s [P536].
69. Moretti M. Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation [Abstract]. European Respiratory Journal 2014;44:P293.
70. Pirabbasi E, Shahar S, Manaf ZA, Rajab NF, Manap RA. Efficacy of ascorbic acid (vitamin C) and/N-acetylcysteine (NAC) supplementation on nutritional and antioxidant status of male chronic obstructive pulmonary disease (COPD) patients. Journal of Nutritional Science and Vitaminology 2016;62(1):54-61.
71. Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 1996;109(2):348-52.
72. Saibene F, Paone G, Lanata L, Puglisi G, Moscatelli B, Colli RD. Effect of carbocysteine lysine salt on frequency of exacerbations in COPD patient treated with or without inhaled steroids. European Respiratory Journal 2016;48: PA544.
73. Salve VT, Atram JS. N-Acetylcysteine combined with home based physical activity: Effect on health related quality of life in stable COPD patients-a randomised controlled trial. Journal of Clinical and Diagnostic Research 2016;10(12): OC16-OC19.
74. Sushko V, Shvaiko L, Bazyka K, Riazhska A. Treatment of chronic obstructive pulmonary disease in clean-up workers of the Chornobyl NPP accident in the remote period after irradiation with additional 6 month prescription combination of ambroxol and essential phospholipids. European Respiratory Journal 2016;48:PA4299.
75. Sushko VO, Shvaiko LI, Bazyka KD, Riazhska AS. Optimization of chronic obstructive pulmonary disease treatment in clean-up workers of the Chornobyl NPP accident in the remote period after irradiation. Problemy Radiatsiinoi Medytsyny Ta Radiobiolohii 2015;20:457-66.
76. Tatsumi K, Fukuchi Y. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. Journal of the American Geriatrics Society 2007;55(11): 1884-5.
77. Tatsumi K, Fukuchi Y. Carbocisteine reduces the frequency of exacerbations in patients with COPD: Findings from the PEACE study. American Thoracic Society International Conference; 2007; May 18-23; San Francisco. 2007:C97.
78. Velazquez A, Aguilar G, Sanchez C, Ochoa L, Sansores R, Remirez-Venegas A. The mucolytic effect on quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine 2001;163(5 Suppl):A57.
79. Wilhelmi E. Treatment of COPD: Benefit of 1.8 cineole as co medication confirmed [Behandlung der COPD: Nutzen voan 1.8-cineol als zusatztherapie bestatigt]. Journal Pharmakol U Ther 2010;2:554-5.
80. Hussain A, Rizvi W. Comparative Evaluation of Efficacy and Safety Profile of Antioxidants-N-Acetyl-L-Cysteine (NAC) and Superoxide Dismutase (SOD) Supplementation in Patients of COPD. Clinical Trials Registry-India 2015.
81. Early Intervention With Carbocysteine and Low Dose Theophylline in Chinese PatientsWith Chronic Obstructive Pulmonary Disease. Chinese Clinical Trials Registry 2018.
82. Zhou Y, Ran P. Long-Term Regular Treatment of Early COPD With Randomized, Double-Blind, Placebo- Controlled Multicenter Clinical Study With Acetylcysteine Effervescent Tablets. Chinese Clinical Trial Registry 2017.
83. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G. Effects of aerosolized surfactant in patients with stable chronic bronchitis: A prospective randomized controlled trial. Journal of American Medical Association 1997;278(17):1426-31.
84. Ballabio M, Nicola M, Moretti M. Long-term use of antioxidant mucolytic erdosteine is especially beneficial in patient with more severe COPD. European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008: Abstract ERS08L1˙678.
85. Cates CJ. Simpson’s paradox and calculation of number needed to treat from meta-analysis. BMC Medical Research Methodology 2002;2:1. DOI: 10.1186/1471-2288-2-1
86. Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: A meta-analysis. European Respiratory Review 2015;24(137):451-61.
87. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1997;156(6): 1719-24.
88. Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, et al. Prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015;147(4):883-93.
89. Fowdar K, Chen H, He Z, Zhang J, Zhong X, Zhang J, et al. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review. Heart and Lung 2017;46(2):120-8.
90. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf (accessed before 14 December 2018).
91. Grandjean EM, Berthet PH, Ruffman R, Leuenberger PH. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials. Clinical Therapeutics 2000;22(2):209-20.
92. Grandjean EM, Berthet PH, Ruffman R, Leuenberger PH. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacology Research 2000;42(1):39-50.
93. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42(10):773-88.
94. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. [Available from www.handbook.cochrane.org]
95. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: The St. George’s Respiratory Questionnaire. American Review of Respiratory Disease 1992;145(6):1321-7.
96. Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD 2005;2(1):75-9.
97. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. American Journal of Respiratory and Critical Care Medicine 2013;189(3):250-5.
98. Li X, Sun H, Liu C, Kang J. Mucolytic and antioxidant agents for exacerbations of chronic obstructive pulmonary disease: A meta-analysis. Chinese Journal of Tuberculosis and Respiratory Diseases 2015;38(8):600-6.
99. Moretti M, Nicola M. Prevention of COPD exacerbations and reduction of health care utilization with erdosteine. European Respiratory Journal 2007;30(Suppl 51):557s.
100. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: Diagnosis and management. www.nice.org.uk/guidance/ng115 (accessed before 14 December 2018).
101. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine 2011;155(3):179-91.
102. Rahman I. Oxidative stress in the pathogenesis of chronic obstructive pulmonary disease; cellular and molecular mechanisms. Cell Biochemistry and Biophysics 2005;43(1): 167-88.
103. Rennard SI, Vestbo J. COPD: The dangerous underestimate of 15%. Lancet 2006;367(9518):1216-9.
104. Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respiratory Care 2007;52:859-65.
105. Rubin BK. Secretion properties, clearance, and therapy in airway disease. Translational Respiratory Medicine 2014;2:6.
106. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review. European Respiratory Journal 2000;16(2):253-62.
107. van Agteren JEM, Carson KV, Tiong LU, Smith BJ. Lung volume reduction surgery for diffuse emphysema. Cochrane Database of Systematic Reviews 2016, Issue 10. DOI: 10.1002/14651858.CD001001.pub3
108. Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, et al. Prevention of COPD exacerbations: A European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal 2017;50(3):pii: 1602265.
109. World Health Organization. The top 10 causes of death. www.who.int/mediacentre/factsheets/fs310/en/ (accessed before 14 December 2018).
110. Yang IA, Brown JL, George J, Jenkins S, McDonald CF, McDonald V, et al. The COPD-X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease. Version 2.53. copdx.org.au/wp-content/uploads/2018/11/COPDX-V2-55-Aug-2018.pdf (accessed before 13 December 2018).
111. Poole PJ, Black PN. The effect of mucolytic agents on exacerbation frequency in chronic bronchitis. Cochrane Database of Systematic Reviews 1998, Issue 4. DOI: 10.1002/14651858.CD001287
112. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis. Cochrane Database of Systematic Reviews 1999, Issue 2. DOI: 10.1002/14651858.CD001287
113. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: Systematic review. BMJ 2001;322:1271-4.
114. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3. DOI: 10.1002/14651858.CD001287.pub2
115. Poole PJ, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 8. DOI: 10.1002/14651858.CD001287
116. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015, Issue 7. DOI: 10.1002/14651858.CD001287.pub5